A tragic medical saga unfolds in Colombo, where families are seeking justice and answers after losing loved ones. The Daily Mirror reports on the ongoing battle for compensation, shedding light on a controversial incident involving the Ondansetron injections.
Two families have come forward, demanding compensation for the loss of their loved ones, who passed away after receiving Ondansetron injections. The husband of one victim has filed a complaint with the Criminal Investigation Department (CID), urging a thorough investigation into this matter.
But here's where it gets controversial... The authorities are in a dilemma, as they await the results of laboratory tests on the withdrawn drug batches. Without these results, they are hesitant to take further action. Dr. Ananda Wijewickrama, Chairman of the National Medicines Regulatory Authority (NMRA), emphasizes the need for comprehensive test results before drawing any conclusions.
Amidst this investigation, the Indian manufacturer of Ondansetron has requested to send samples for global testing. The NMRA is taking steps to upgrade its laboratory facilities to meet WHO accreditation standards, ensuring the highest level of scrutiny.
And this is the part most people miss... Sri Lanka is considering a proposal from Maan Pharmaceutical (Pvt) Ltd., the manufacturer of the Ondansetron in question. The company has offered to bear the full cost of referring the withdrawn batches to an internationally recognized laboratory for independent testing. Dr. Wijewickrama confirms that this request is being reviewed by the Medicines Evaluation Committee, and a decision will be made based on their recommendations.
On December 13, the NMRA took swift action, ordering the immediate withdrawal of four batches of Ondansetron injections manufactured by Maan Pharmaceutical from both state and private hospitals. This decision was made due to suspicions of possible contamination.
The authorities emphasize that investigations are still ongoing, and decisions regarding accountability and compensation will be made based on the outcomes of laboratory analyses and expert evaluations. This case highlights the complex process of determining liability in medical incidents and the importance of thorough investigations.
As this story unfolds, it raises questions about the role of pharmaceutical companies, the responsibility of regulatory bodies, and the rights of patients and their families. What do you think? Should pharmaceutical companies be held more accountable for their products? Share your thoughts in the comments below!
